JP Morgan Maintains Overweight on Merck & Co, Raises Price Target to $165

Benzinga Newsdesk www.benzinga.com Positive 76.8%

Neg 0% Neu 0% Pos 76.8%

JP Morgan analyst Chris Schott maintains Merck & Co (NYSE:MRK) with a Overweight and raises the price target from $150 to $165.